Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bristol-Myers Squibb
Long-term data provides guidance on use of Sustiva in HIV treatment
September 24th, 2004
Bristol-Myers Squibb Company (NYSE:BMY) announced that SUSTIVA (efavirenz) has received approval from the U.S. Food and Drug Administration (FDA) to include new long-term virologic and clinical data from BMS Study 006 in its prescribing information. The new data demonstrate the long-term durability of virologic response in people living with HIV-1 who are naive to protease inhibitors, lamivudine (3TC) and non-nucleoside reverse transcriptase inhibitors (NNRTI) through more than 3 years of treatment on a combination regimen containing SUSTIVA. "The new data from Study 006 provide valuable information to healthcare professionals supporting first-line...
Source: Food & Drug Law Weekly (2004-09-24)
|
